Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies
This study is a single center, single arm, prospective, phase II clinical study to evaluate the efficacy and safety of Venatoclax combined with reduced intensity conditioning regimen allo-HSCT in the treatment of high-risk myeloid malignancies in the elderly patients.
Leukemia, Myeloid, Acute|MDS|Hematopoietic Stem Cell Transplantation|Myeloid Malignancy
DRUG: Venetoclax plus RIC
PFS, Progression free survival for all patients enrolled, 1- year PFS|PFS, Progression free survival for all patients enrolled, 2- year PFS
OS, Overall survival for all patients enrolled, 1- year OS|OS, Overall survival for all patients enrolled, 2- year OS|aGVHD rate, The incidence rate of acute GVHD after transplantation, 180 days after transplantation|cGVHD rate, The incidence rate of chronic GVHD after transplantation, 1 year after transplantation|cGVHD rate, The incidence rate of chronic GVHD after transplantation, 2 years after transplantation|Relapse rate, Cumulative relapse rate after transplantation, 1 year after transplantation|NRM, Non relapse mortality after transplantation, 2 years after transplantation|GVHD-free relapse-free survival(GRFS), Time from transplantation to the diagnosis of chronic GVHD or relapse, 2 years after transplantation|Reactivation rate of EBV and CMV, Reactivation rate of Epstein-Barr virus and cytomegalovirus after transplantation, 1 year after transplantation|Reactivation rate of EBV and CMV, Reactivation rate of Epstein-Barr virus and cytomegalovirus after transplantation, 2 years after transplantation
Eligible patients will receive Venetoclax plus RIC regimen allogeneic transplantation. The treatment regimen is: Venetoclax 100mg/d - 10d, 200mg/d - 9d (first use and NR or untreated MDS), 400mg/d, - 8d\~ - 2d (7d); Fludarabine: 30mg/m2/d, - 6d\~-2d (5d), Cytarabine: 1g/m2/d, - 6d\~-2d (5d) Busulfan: 3.2mg/m2/d, - 6d\~-5d (2d), total body irradiation(TBI): 3 Gray, - 1d.

Primary end point: 1 year and 2 year progression free survival (PFS) after transplantation. Secondary end point: incidence of acute GVHD within 180 days after transplantation; cumulative rate of relapse, overall survival(OS), graft-versus-host disease (GVHD)-free relapse-free survival(GRFS), non-relapse mortality(NRM), and incidence of chronic GVHD at 1 and 2 years after transplantation; The reactivation rate of cytomegalovirus(CMV) and Epstein-Barr virus (EBV) within 1 year after transplantation.